Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5615411 | Journal of Clinical Lipidology | 2016 | 11 Pages |
Abstract
TA-8995 dose dependently increased not only total and non-ABCA1-specific CEC but also ABCA1-specific CEC and preBeta-1 HDL particle levels. These findings suggest that TA-8995 not only increases HDL-C levels but also promotes functional properties of HDL particles. This CETP inhibitor-driven preBeta-1 HDL increase is an important predictor of both ABCA1 and total CEC increase, independent of HDL-C increase. Whether these changes in HDL particle composition and functionality have a beneficial effect on cardiovascular outcome requires formal testing in a cardiovascular outcome trial.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Julian C. MD, John J.P. MD, PhD, Aeilko H. PhD, Sander J.H. MD, PhD, Heidi L. PhD, Steven J. PhD, Patrick PhD, John PhD, Daniel J. MD, PhD, G. Kees MD, PhD,